Don't Forget To
Rate This Article

AAA_Awakn - pending

Healthcare ServicesBiotechnology / Pharmaceuticals

Source: Streetwise Reports (7/15/22)

Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity
Source: Streetwise Reports (07/18/2022)

One junior biotech company that attempts to treat current health problems with older previously approved drugs, recently completed a Phase 2 study that showed promise in the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough. It moved the small company a step closer to bringing the treatment to market.

ScPharmaceuticals Inc. just released topline results from a Phase 2 pilot study supporting the drug developer that is pursuing the expansion of its new drug label, noted an H.C. Wainwright & Co. report.

Pharma Co. Reduces Mortality Rates by 70% in ALS Trial
Source: Streetwise Reports (07/15/2022)

Shares of Clene Inc. traded 38% higher yesterday after the company reported that its CNM-Au8 was shown to significantly decrease mortality in its RESCUE-ALS long-term extension trial.

Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’
Source: Patrick Trucchio (07/15/2022)

Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with Alcohol Use Disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD.

Biopharma Co. Posts 17% BMI Reduction in Ph. 2 Trial
Source: Streetwise Reports (07/14/2022)

Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its Phase 2 clinical study of setmelanotide in hypothalamic obesity. The data shows that after 16 weeks of treatment with setmelanotide, patients experienced a 17.2% mean reduction in BMI and a mean weight loss of 15.8%.